Advancing Biopharma R&D, Business Analytics, and Decision Making

Portfolio prioritization, decision analysis, agile capacity management, resource forecasting, risk mitigation, and overall strategic decision making are becoming increasing difficult in today’s ever-changing pharma R&D landscape. Cambridge Healthtech Institute’s Biopharma Strategy Series presents Executive Decision Making for Pharma and Biotech 2023, 3 days of high-level content, interactive discussions and networking, breakout roundtables, 1:1 meetings, and much more! Attendees will leave with new tools and organizational strategies to optimize portfolio insights and decision making; and align resource planning, allocation, and capacity management with portfolio prioritization.  

2022 Advisory Board

Michael Ferrante

Michael Ferrante

Executive Director, Portfolio Prioritization, Global Regulatory Affairs & Clinical Safety, Merck

Samantha Fairbairn

Samantha Fairbairn

Executive Director, Business Performance - Integrated Portfolio Advancement, Amgen

Kevin Doyle

Kevin Doyle

Director, Business Analytics & Capacity Management, Janssen Pharmaceuticals

Michael Myers

Michael Myers

Associate Vice President, LRL Project Management - Due Diligence, Eli Lilly & Co.


"This conference attracted a great set of attendees from companies and from vendors--the best that I have ever attended. As such, it was a great opportunity to learn from others and to catch up on broad trends. My perspective shifted from being focused 1-3 years out to really thinking about the longer term, and how to get my company from where we are today to where we need to be in the long term."
Biopharma Portfolio Manager, 2022 Attendee

Alumni Organizations